MapLight's ML-007C-MA hits primary endpoint in Phase 2 ZEPHYR schizophrenia trial

MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia on 27 July 2026. The registration-designed study, in adults hospitalised with an acute exacerbation of schizophrenia, met its primary endpoint: the 210/3 mg twice-daily (BID) dose delivered a least-squares mean difference of -4.5 points in PANSS total score change versus placebo at Week 5 in the modified intent-to-treat population (p=0.015; Cohen's d 0.37).

ML-007C-MA is a novel M1/M4 muscarinic acetylcholine receptor agonist based on xanomeline, paired with a peripheral antagonist to improve tolerability - the same mechanistic class that has renewed interest in muscarinic therapies for psychosis after decades dominated by dopamine-blocking antipsychotics. The company also reported improvements in cognition alongside the symptom benefit.

The topline readout supports advancement toward a registrational programme. MapLight, based in Redwood City, California, listed publicly earlier in 2026.